PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia

European Neuropsychopharmacology

Volumn 23, Issue 3, 2013, Pages 253-262

  Beyaert, Michael G R ^a   Daya, Ritesh P ^a   Dyck, Bailey A ^a   Johnson, Rodney L ^b   Mishra, Ram K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Allosteric regulation; Amphetamine; Animal models; Dopamine D2 receptor; PAOPA; Schizophrenia

Indexed keywords

[3 [(2 PYRROLIDINYLCARBONYL)AMINO] 2 OXO 1 PYRROLIDINEACETAMIDE]; AMPHETAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; PAOPA; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; DISEASE MODEL; DRUG SENSITIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ALLOSTERIC REGULATION; AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; MALE; MOTOR ACTIVITY; NEOSTRIATUM; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 84875252587     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.04.010     Document Type: Article

References (53)

1. Abi-Dargham A., van de Giessen E., Slifstein M., Kegeles L.S., Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol. Psychiatry 2009, 65:1091-1093.
2. Beatty W.W., Costello K.B., Berry S.L. Suppression of play fighting by amphetamine: effects of catecholamine antagonists, agonists and synthesis inhibitors. Pharmacol. Biochem. Behav. 1984, 20:747-755.
3. Benneyworth M.A., Xiang Z., Smith R.L., Garcia E.E., Conn P.J., Sanders-Bush E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol. Pharmacol. 2007, 72:477-484.
4. Brady A.E., Jones C.K., Bridges T.M., Kennedy J.P., Thompson A.D., Heiman J.U., Breininger M.L., Gentry P.R., Yin H., Jadhav S.B., Shirey J.K., Conn P.J., Lindsley C.W. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J. Pharmacol. Exp. Ther. 2008, 327:941-953.
5. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U S A 1997, 94:2569-2574.
6. Buchanan R.W., Conley R.R., Dickinson D., Ball M.P., Feldman S., Gold J.M., McMahon R.P. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am. J. Psychiatry 2008, 165:82-89.
7. Cass W.A., Bowman J.P., Elmund J.K. Behavior, striatal and nucleus accumbens field potential patterns and dopamine levels in rats given amphetamine continuously. Neuropharmacology 1989, 28:217-227.
8. Chan W.Y., McKinzie D.L., Bose S., Mitchell S.N., Witkin J.M., Thompson R.C., Christopoulos A., Lazareno S., Birdsall N.J., Bymaster F.P., Felder C.C. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl. Acad. Sci. U S A 2008, 105:10978-10983.
9. Conn P.J., Christopoulos A., Lindsley C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discovery 2009, 8:41-54.
10. Daumit G.L., Goff D.C., Meyer J.M., Davis V.G., Nasrallah H.A., McEvoy J.P., Rosenheck R., Davis S.M., Hsiao J.K., Stroup T.S., Lieberman J.A. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr. Res. 2008, 105:175-187.
11. Dyck B., Guest K., Sookram C., Basu D., Johnson R., Mishra R.K. PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in schizophrenia. Schizophr. Res. 2011, 125:88-92.
12. Galici R., Jones C.K., Hemstapat K., Nong Y., Echemendia N.G., Williams L.C., de Paulis T., Conn P.J. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther. 2006, 318:173-185.
13. Gambill J.D., Kornetsky C. Effects of chronic d-amphetamine on social behavior of the rat: implications for an animal model of paranoid schizophrenia. Psychopharmacology (Berlin) 1976, 50:215-223.
14. Geyer M.A. The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps?. Neurotox. Res. 2006, 10:211-220.
15. Gill K.M., Lodge D.J., Cook J.M., Aras S., Grace A.A. A novel alpha5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology 2011, 36:1903-1911.
16. Grillon C., Ameli R., Charney D.S., Krystal J., Braff D. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol. Psychiatry 1992, 32:939-943.
17. Hoare S.R., Coldwell M.C., Armstrong D., Strange P.G. Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br. J. Pharmacol. 2000, 130:1045-1059.
18. Hoare S.R., Strange P.G. Regulation of D2 dopamine receptors by amiloride and amiloride analogs. Mol. Pharmacol. 1996, 50:1295-1308.
19. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35:549-562.
20. Kenakin T. G protein coupled receptors as allosteric proteins and the role of allosteric modulators. J. Recept. Signal Transduct. Res. 2010, 30:313-321.
21. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U S A 1996, 93:9235-9240.
22. Lecourtier L., Homayoun H., Tamagnan G., Moghaddam B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-methyl-d-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol. Psychiatry 2007, 62:739-746.
23. Mailman R.B., Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?. Curr. Pharm. Des. 2010, 16(5):488-501.
24. Marcotte E.R., Chugh A., Mishra R.K., Johnson R.L. Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1). Peptides 1998, 19(2):403-406.
25. Meller E., Bohmaker K., Namba Y., Friedhoff A.J., Goldstein M. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol. Pharmacol. 1987, 31:592-598.
26. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 1991, 17:263-287.
27. Meyer J.M., Davis V.G., Goff D.C., McEvoy J.P., Nasrallah H.A., Davis S.M., Rosenheck R.A., Daumit G.L., Hsiao J., Swartz M.S., Stroup T.S., Lieberman J.A. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr. Res. 2008, 101:273-286.
28. Miller D.D., Caroff S.N., Davis S.M., Rosenheck R.A., McEvoy J.P., Saltz B.L., Riggio S., Chakos M.H., Swartz M.S., Keefe R.S., Stroup T.S., Lieberman J.A., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Extrapyramidal side-effects of antipsychotics in a randomised trial. Br. J. Psychiatry 2008, 193:279-288.
29. Mishra R.K., Makman M.H., Costain W.J., Nair V.D., Johnson R.L. Modulation of agonist stimulated adenylyl cyclase and GTPase activity by l-pro-l-leu-glycinamide and its peptidomimetic analogue in rat striatal membranes. Neurosci. Lett. 1999, 269:21-24.
30. 2 (PLG). Peptides 1997, 18:1209-1215.
31. Mishra R.K., Srivastava L.K., Johnson R.L. Modulation of high-affinity CNS dopamine D2 receptor by l-pro-l-leu-glycinamide (PLG) analogue 3(R)-(N-l-prolylamino)-2-oxo-1-pyrrolidineacetamide. Prog. Neuropsychopharmacol. Biol. Psychiatry 1990, 14:821-827.
32. Mukherjee J., Christian B.T., Narayanan T.K., Shi B., Mantil J. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 2001, 25:476-488.
33. Ott M.C., Costain W.J., Mishra R.K., Johnson R.L. L-prolyl-l-leucyl- glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]- 2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum. Peptides 2000, 21(2):301-308.
34. Paulson P.E., Camp D.M., Robinson T.E. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology (Berlin) 1991, 103:480-492.
35. Paulson P.E., Robinson T.E. Sensitization to systemic amphetamine produces an enhanced locomotor response to a subsequent intra-accumbens amphetamine challenge in rats. Psychopharmacology (Berlin) 1991, 104:140-141.
36. Peleg-Raibstein D., Sydekum E., Russig H., Feldon J. Withdrawal from repeated amphetamine administration leads to disruption of prepulse inhibition but not to disruption of latent inhibition. J. Neural Transm. 2006, 113:1323-1336.
37. Peleg-Raibstein D., Yee B.K., Feldon J., Hauser J. The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms?. Psychopharmacology (Berlin) 2009, 206:603-621.
38. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav. Pharmacol. 1995, 6:55-65.
39. Sams-Dodd F. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 1998, 19:18-25.
40. Schilstrom B., Ivanov V.B., Wiker C., Svensson T.H. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 2007, 32:43-53.
41. Seeman P. Dopamine D2High receptors measured ex vivo are elevated in amphetamine-sensitized animals. Synapse 2009, 63:186-192.
42. Seeman P., Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc. Natl. Acad. Sci. U S A 2000, 97:7673-7675.
43. Sharma S., Paladino P., Gabriele J., Saeedi H., Henry P., Chang M., Mishra R.K., Johnson R.L. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: a model of human tardive dyskinesia. Peptides 2003, 24:313-319.
44. Simpson E.H., Kellendonk C., Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 2010, 65:585-596.
45. Soriano A., Vendrell M., Gonzalez S., Mallol J., Albericio F., Royo M., Lluis C., Canela E.I., Franco R., Cortes A., Casado V. A hybrid indoloquinolizidine peptide as allosteric modulator of dopamine D1 receptors. J. Pharmacol. Exp. Ther. 2010, 332:876-885.
46. Soriano A., Ventura R., Molero A., Hoen R., Casado V., Cortes A., Fanelli F., Albericio F., Lluis C., Franco R., Royo M. Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers. J. Med. Chem. 2009, 52:5590-5602.
47. Steinpreis R.E., Sokolowski J.D., Papanikolaou A., Salamone J.D. The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat. Pharmacol. Biochem. Behav. 1994, 47:579-585.
48. Tenn C.C., Fletcher P.J., Kapur S. Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr. Res. 2003, 64:103-114.
49. Tenn C.C., Kapur S., Fletcher P.J. Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. Psychopharmacology (Berlin) 2005, 180:366-376.
50. Verma V., Mann A., Costain W., Pontoriero G., Castellano J.M., Skoblenick K., Gupta S.K., Pristupa Z., Niznik H.B., Johnson R.L., Nair V.D., Mishra R.K. Modulation of agonist binding to human dopamine receptor subtypes by l-prolyl-l-leucyl-glycinamide and a peptidomimetic analog. J. Pharmacol. Exp. Ther. 2005, 315:1228-1236.
51. Wang L., Martin B., Brenneman R., Luttrell L.M., Maudsley S. Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders. J. Pharmacol. Exp. Ther. 2009, 331:340-348.
52. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 1996, 2:699-703.
53. 2. J. Med. Chem. 1988, 31:1430-1436.